New DDDs 2020
ATC code | ATC level name | New DDD | ||
---|---|---|---|---|
V03AE10 | sodium zirconium cyclosilicate | 7.5 | g | O |
P01CA03 | fexinidazole | 1.44 | g | O |
N02CD03 | fremanezumab | 7.5 | mg | P |
N02CD02 3) | galcanezumab | 4 | mg | P |
N02CD01 2) | erenumab | 2.5 | mg | P |
M04AB05 | lesinurad | 0.2 | g | O |
M03BX03 | pridinol | 6 | mg | O |
L04AC12 | brodalumab | 15 | mg | P |
L04AB07 | opinercept | 7 | mg | P |
L02BB05 | apalutamide | 0.24 | g | O |
J05AX27 | favipiravir | 1.6 | g | O |
J05AX26 | amenamevir | 0.4 | g | O |
J05AX25 | baloxavir marboxil | 40 | mg | O |
J05AP11 | grazoprevir | 0.1 | g | O |
J05AP10 | elbasvir | 50 | mg | O |
J05AP06 | asunaprevir | 0.2 | g | O |
J05AH04 | laninamivir | 40 | mg | Inhal.powder |
J05AH03 | peramivir | 0.6 | g | P |
J05AG06 | doravirine | 0.1 | g | O |
J05AB03 | vidarabine | 0.7 | g | P |
J04AB06 | enviomycin | 1 | g | P |
J04AA03 | calcium aminosalicylate | 15 | g | O |
J01MA12 | levofloxacin | 0.24 | g | Inhal.solution |
J01DD64 | cefpodoxime and beta-lactamase inhibitor | 0.4 1) | g | O |
J01AA15 | omadacycline | 0.1 | g | P |
J01AA15 | omadacycline | 0.3 | g | O |
J01AA14 | sarecycline | 0.1 | g | O |
G04BX15 | pentosan polysulfate sodium | 0.3 | g | O |
G03XX01 | prasterone | 6.5 | mg | V |
A16AX09 | glycerol phenylbutyrate | 15 | g | O |
A16AB17 | cerliponase alfa | 21 | mg | P |
A10BJ06 | semaglutide | 0.11 | mg | P |
A04AD11 | nabilone | 3 | mg | O |
1) Refers to cefpodoxime
2) Previous ATC code N02CX07, new ATC 4th level N02CD valid from January 2020
3) Previous ATC code N02CX08, new ATC 4th level N02CD valid from January 2020.
2) Previous ATC code N02CX07, new ATC 4th level N02CD valid from January 2020
3) Previous ATC code N02CX08, new ATC 4th level N02CD valid from January 2020.
Last updated: 2019-12-13